129
Participants
Start Date
March 11, 2019
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2027
Azer-cel
Infusion of Allogeneic Anti-CD19 CAR T cells
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
IL-2
Specified dose on specified days
Bendamustine
Specified dose on specified days
RECRUITING
Royal Prince Alfred Hospital, Camperdown
NOT_YET_RECRUITING
Liverpool Hospital, Liverpool
RECRUITING
St Vincent's Hospital Melbourne, Fitzroy
RECRUITING
Royal Adelaide Hospital, Adelaide
ACTIVE_NOT_RECRUITING
Weill Cornell Medical College - NY Presbyterian Hospital, New York
RECRUITING
Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
RECRUITING
University of Maryland, Baltimore
COMPLETED
Duke University, Durham
RECRUITING
Winship Cancer Institute Emory University, Atlanta
RECRUITING
Northside Hospital Cancer Institute, Atlanta
RECRUITING
H. Lee Moffitt Cancer Center, Tampa
RECRUITING
Ohio State University, Columbus
RECRUITING
Barbara Ann Karmanos Cancer Institute (Wayne State University), Detroit
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
University of Minnesota, Minneapolis
RECRUITING
Baylor University Medical Center, Dallas
COMPLETED
MD Anderson, Houston
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
City of Hope, Duarte
RECRUITING
Tufts Medical Center, Boston
COMPLETED
Dana-Farber Cancer Institute, Boston
RECRUITING
Lifespan Cancer Institute at Rhode Island Hospital, Providence
Imugene Limited
INDUSTRY